This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
Investigators at the National Cancer Institute''s Vaccine Branch have found that beta-mannosylceramide (Beta-ManCer) promotes immunity in an IFN-gamma independent mechanism and seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize beta-ManCer.
Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown. The National Eye Institute seeks parties interested in licensing or collaborative research to co-develop a process for the production of regulatory B-Cells for use in auto-immune indications.
Researchers at the National Cancer Institute (NCI) have developed an invention consisting of hydrocarbon stapled peptides that disrupt the linear ubiquitin-chain assembly complex (LUBAC), which is involved in NF-κB signaling. These peptides can be used as a therapeutic in the treatment of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma, as well as inflammatory diseases. The NCI seeks licensing and/or co-development research collaborations for inhibitors of NF-κB signaling and/or treatment of ABC DLBCL, as well as inflammatory diseases.
The Laboratory of Cardiovascular Sciences of the National Institute on Aging, is seeking parties interested in licensing or collaborative research to co-develop a cell surface protein observed to reduce inflammation and related injuries. In vivo and in vitro data are available.
IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
Researchers at the National Cancer Institute, Laboratory of Molecular Immunoregulation developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens.The National Cancer Institute, Laboratory of Molecular Immunoregulation seeks parties interested in licensing or collaborative research to co-develop polypeptides or antagonists for immune response regulation.
The National Cancer Institute’s Laboratory of Immune Cell Biology seeks partners interested in licensing or collaborative research to co-develop peptide-based therapeutics for inflammatory autoimmune conditions or inflammatory cancers.
Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010
Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.
Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).
Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.
Researchers at the National Cancer Institute (NCI) developed compounds containing both a non-steroidal anti-inflammatory drug (NSAID) and a nitroxyl (HNO) -releasing agent that have significantly reduced toxicity, allowing their use for extended periods of time without severe side effects.The HNO-releasing moiety contained in this invention may expand the medical utility of NSAIDs. HNO releasing agents possess anticancer activity as well as good antioxidant properties, which has potential benefit for a variety of human diseases, including acute and chronic inflammation. NCI seeks parties to license or co-develop this technology.
Researchers at the National Cancer Institute (NCI) developed a treatment regimens for cancer and HIV using heterodimeric IL-15 (hetIL-15). The regimens allow access to B cell follicles, germinal centers, and tumor sites that are difficult for drug entry. A combination therapy for HIV infection is also described using hetIL-15 and a conserved element vaccine. Researchers seek licensing and/or co-development research collaborations for development and commercialization of treatment regimens for HIV infection.
Researchers at the National Institutes on Aging (NIA) seek research co-development or licensees for novel compounds and pharmaceutical formulations to treat autoimmune disorder and inflammation. Other potential indications for these compounds include pain, itching, and/or skin disorders.